Log on / register
Feedback | Support | My details
Open AccessHighly AccessResearch article

EDTA chelation therapy for cardiovascular disease: a systematic review

Dugald MR Seely1,2 email, Ping Wu2,3 email and Edward J Mills4 email

Canadian College of Naturopathic Medicine, Toronto, Canada

Institute of Medical Science, University of Toronto, Toronto, Canada

London School of Hygiene and Tropical medicine, University of London, UK

Department of Clinical Epidemiology & Biostatistics, McMaster University, Hamilton, Canada

author email corresponding author email

BMC Cardiovascular Disorders 2005, 5:32doi:10.1186/1471-2261-5-32

Published: 1 November 2005

Abstract

Background

Numerous practitioners of both conventional and complementary and alternative medicine throughout North America and Europe claim that chelation therapy with EDTA is an effective means to both control and treat cardiovascular disease. These claims are controversial, and several randomized controlled trials have been completed dealing with this topic. To address this issue we conducted a systematic review to evaluate the best available evidence for the use of EDTA chelation therapy in the treatment of cardiovascular disease.

Methods

We conducted a systematic review of 7 databases from inception to May 2005. Hand searches were conducted in review articles and in any of the trials found. Experts in the field were contacted and registries of clinical trials were searched for unpublished data. To be included in the final systematic review, the studies had to be randomized controlled clinical trials.

Results

A total of seven articles were found assessing EDTA chelation for the treatment of cardiovascular disease. Two of these articles were subgroup analyses of one RCT that looked at different clinical outcomes. Of the remaining five studies, two smaller studies found a beneficial effect whereas the other three exhibited no benefit for cardiovascular disease from the use of EDTA chelation therapy. Adverse effects were rare but those of note included a few cases of hypocalcemia and a single case of increased creatinine in a patient on the EDTA intervention.

Conclusion

The best available evidence does not support the therapeutic use of EDTA chelation therapy in the treatment of cardiovascular disease. Although not considered to be a highly invasive or harmful therapy, it is possible that the use of EDTA chelation therapy in lieu of proven therapy may result in causing indirect harm to the patient.


© 1999-2009 BioMed Central Ltd unless otherwise stated. Part of Springer Science+Business Media.